LuciDabra (Dabrafenib) 75mg | Generic BRAF Inhibitor | Lucius Pharmaceuticals (Lao) Co., Ltd. | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

LuciDabra is Lucius Pharmaceuticals' generic dabrafenib, manufactured at the company's facility in Laos. It provides the 75 mg capsule of this BRAF inhibitor as a cost-conscious option for BRAF-mutant cancer patients, with the same active ingredient and dosing as the originator Tafinlar.

Generic Information: LuciDabra (Dabrafenib)

Lucius Pharmaceuticals (Lao) Co., Ltd. is a specialty pharmaceutical company with a broad portfolio of targeted oncology generics. Its "Luci" product family spans many modern cancer agents, and LuciDabra is its dabrafenib offering. The company serves both its home market and a wide export network across Asia and beyond, positioning itself as an accessible source of newer cancer therapies.

What Is LuciDabra (Dabrafenib) Used For?

LuciDabra is used for cancers that depend on a BRAF V600 mutation. The principal indications are unresectable or metastatic melanoma, and — with trametinib — BRAF V600E-mutated metastatic non-small cell lung cancer and anaplastic thyroid cancer.

How Does LuciDabra Work?

The dabrafenib in LuciDabra selectively blocks mutant BRAF kinase, turning off the overactive MAPK pathway that drives BRAF-mutant tumors. This suppresses tumor growth and can induce cancer-cell death; combining it with a MEK inhibitor amplifies and prolongs the response.

Indications

  • BRAF V600-mutant unresectable or metastatic melanoma
  • Adjuvant melanoma therapy with trametinib
  • BRAF V600E metastatic NSCLC with trametinib
  • BRAF V600E anaplastic thyroid cancer with trametinib

Dosage & Administration

The standard dose is 150 mg twice daily (two 75 mg capsules per dose), with or without food. Capsules are swallowed whole. Any dose change is directed by the oncologist.

Side Effects

Fever, fatigue, rash, nausea, headache, chills and joint pain are the common reactions. Serious risks include new skin cancers, bleeding, cardiomyopathy, uveitis and elevated blood sugar. Skin and temperature monitoring should continue throughout therapy.

Storage & Handling

Keep at room temperature in the original package, away from moisture and light, out of children's reach, and not past the expiry date.

Why Choose LuciDabra?

  • Lucius generic — a trusted name in Lao oncology generics.
  • 75 mg standard strength — matches the originator's dosing.
  • Cost-effective — lower-priced dabrafenib for ongoing therapy.

How to Order LuciDabra from GLT

  1. Contact GLT via WhatsApp +86 15234153837 or email [email protected] with quantity and destination.
  2. Receive a quotation and delivery estimate.
  3. Complete payment via Hao Yi Lian / 好易联.
  4. Dispatch with documentation and tracking.

A valid prescription may be requested before dispatch. Institutions and individual patients are both served.

FAQ

1. Who makes LuciDabra?

LuciDabra is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd.

2. Is LuciDabra a generic of Tafinlar?

Yes, it is a generic dabrafenib with the same 75 mg active ingredient and dosing.

3. Do I need a prescription?

Yes, dabrafenib is prescription-only, and a prescription may be requested before dispatch.

Related Oncology Products

Palutini (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Trans Continental Life Science & Pharmaceuticals (TLPH) (Laos) — an...

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

Barinib (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Drug International Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Drug International Limited (Bangladesh) — an affordable alternative to Olumiant...

Avabopa (Avatrombopag) 20mg*30 Tablets | Tongmeng TLPH Laos | GLT

Avabopa — avatrombopag 20mg by Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. (TLPH), Lao Reg....

Zepbound (Tirzepatide) 2.5–15mg/0.5mL Single-Dose Pen | Eli Lilly USA | GLT

Zepbound — Eli Lilly tirzepatide single-dose pen, six US strengths (2.5–15mg/0.5mL) for chronic weight management...

AVATODX (Avatrombopag) 20mg*30 Tablets | Bigbear Pharmaceutical Laos | GLT

AVATODX — avatrombopag 20mg by Bigbear Pharmaceutical (Lao) Co., Ltd., Lao Reg. 06L0985/23, 30-tablet bottle

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland